SEARCH

SEARCH BY CITATION

References

  • 1
    Johnston JB. Chronic lymphocytic leukemia. In: GreerJP, FoersterJ, LukensJN, RodgersGM, ParaskevasF, GladerB, eds. Wintrobe's clincial hematology, 11th edn., Vol. 2. Philadelphia: Lippincott, 2004. 242963.
  • 2
    Müller-Hermelink HK, Catovsky D, Montserrat E, Harris NL. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: JaffeES, HarrisNL, SteinH, VardimanJ, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2001. 12730.
  • 3
    Lishner M, Lalkin A, Klein A, Yarkoni S, Manor Y, Fejgin M, Leytin V, Ravid M, Amiel A. The BCL-1, BCL-2, and BCL-3 oncogenes are involved in chronic lymphocytic leukemia. Detection by fluorescence in situ hybridization. Cancer Genet Cytogenet 1995; 85: 11823.
  • 4
    Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 311823.
  • 5
    Strair RK, Sheay W, Goodell L, White E, Rabson AB, Medina DJ. Adenovirus infection of primary malignant lymphoid cells. Leuk Lymphoma 2002; 43: 3749.
  • 6
    Waterhouse D, Carman WJ, Schottenfeld D, Gridley G, McLean S. Cancer incidence in the rural community of Tecumseh, Michigan: a pattern of increased lymphopoietic neoplasms. Cancer 1996; 77: 76370.
  • 7
    Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol 2000; 109: 7949.
  • 8
    Bertoldero G, Scribano G, Podda L, Berti R, Amadori G. Occurrence of second neoplasms in chronic lymphocytic leukemia. Experience at Padua Hospital between 1979 and 1991. Ann Hematol 1994; 69: 1958.
  • 9
    Gu Y, Strom SS, Lerner S, Keating MJ. Second cancers after CLL diagnosis Blood (ASH Annual Meeting Abstracts) 2004; 104:Abstract 18.
  • 10
    Hisada M, Biggar RJ, Greene MH, Fraumeni JF,Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 197981.
  • 11
    Mellemgaard A, Geisler CH, Storm HH. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur J Haematol 1994; 53: 21822.
  • 12
    Travis LB, Curtis RE, Hankey BF, Fraumeni JF,Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 14227.
  • 13
    Adami J, Nyren O, Bergstrom R, Ekbom A, Engholm G, Englund A, Glimelius B. Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden). Cancer Causes Control 1998; 9: 4956.
  • 14
    Schollkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Gadeberg O, Roos G, Porwit-MacDonald A, Glimelius B, Adami HO, Melbye M. Cigarette smoking and risk of non-Hodgkin's lymphoma—a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14: 17916.
  • 15
    Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004; 45: 50713.
  • 16
    Meloni G, Proia A, Guerrisi V, Cordone I, De CR, Fenu S, Mauro FR, Pescarmona E, Reato G, Mandelli F. Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation. Ann Oncol 2000; 11: 14935.
  • 17
    Robak T, Blonski JZ, Gora-Tybor J, Kasznicki M, Konopka L, Ceglarek B, Komarnicki M, Lewandowski K, Hellmann A, Lewandowski K, Moskwa A, Dmoszynska A et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004; 40: 3839.
  • 18
    Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 387884.
  • 19
    Larsen CR, Hansen PB, Clausen NT. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. Am J Hematol 2002; 70: 4850.
  • 20
    Ziprin P, Smith S, Salerno G, Rosin RD. Two cases of merkel cell tumour arising in patients with chronic lymphocytic leukaemia. Br J Dermatol 2000; 142: 5258.
  • 21
    Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry—history, content, quality and use. Dan Med Bull 1997; 44: 5359.
  • 22
    Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma 2005; 46: 4954.
  • 23
    Wiernik PH. Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treat Options Oncol 2004; 5: 21523.
  • 24
    Agnew KL, Ruchlemer R, Catovsky D, Matutes E, Bunker CB. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 112935.
  • 25
    Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310: 14915.
  • 26
    Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005; 97: 199209.
  • 27
    Frentz G, Held E, Østerlind A, Storm HH. Are data on non-melanoma skin cancer comparable among countries? Melanoma Res 1994; 6: S39.
  • 28
    Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252: 20624.
  • 29
    Lagarde F, Axelsson G, Damber L, Mellander H, Nyberg F, Pershagen G. Residential radon and lung cancer among never-smokers in Sweden. Epidemiology 2001; 12: 396404.
  • 30
    Pohlabeln H, Boffetta P, Ahrens W, Merletti F, Agudo A, Benhamou E, Benhamou S, Bruske-Hohlfeld I, Ferro G, Fortes C, Kreuzer M, Mendes A et al. Occupational risks for lung cancer among nonsmokers. Epidemiology 2000; 11: 5328.
  • 31
    Rivera MP, Detterbeck FC, Loong F. Epidemiology and classification of lung cancer. In: DetterbeckFC, RiveraMP, SocinskiMA, RosenmanJG, eds. Diagnosis and treatment of lung cancer, 1st edn. Philadelphia: Saunders, 2001. 2544.
  • 32
    Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, Ryberg D, Haugen A, Olsen JH. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years: a pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 2005; 48: 18799.
  • 33
    Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int J Cancer 2004; 110: 21924.
  • 34
    Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 2005; 221: 18590.
  • 35
    Yuille M, Condie A, Hudson C, Kote-Jarai Z, Stone E, Eeles R, Matutes E, Catovsky D, Houlston R. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002; 99: 42168.
  • 36
    Lung cancer. In: StewartBW, KleihuesP, eds. World cancer report. Lyon: IARC Press, 2003. 1827.
  • 37
    Li X, Hemminki K. Inherited predisposition to early onset lung cancer according to histological type. Int J Cancer 2004; 112: 4517.
  • 38
    Polliack A, Lugassy G. Autoimmunity and auto-immune syndromes associated with and preceding the development of lymphoproliferative disorders. Leukemia 1992; 6 ( Suppl 4): 1524.
  • 39
    Rai KR, Keating MJ. Chronic lymphocytic leukemia. In: BastRC, KufeDW, PollockRE, WeichselbaumRR, HollandJF, FreiE, eds. Holland-Frei cancer medicine, 5th edn. London: Decker, 2000; http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.chapter.33812.
  • 40
    Hall P, Adami H-O. Thyroid cancer. In: AdamiH-O, HunterD, TrichopoulosD, eds. Textbook of cancer epidemiology. New York: Oxford University Press, 2002: 50419.
  • 41
    Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer 2001; 85: 9971005.
  • 42
    Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J Clin Oncol 2006; 24: 156874.
  • 43
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 17507.
  • 44
    Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Weight change and risk of endometrial cancer. Int J Epidemiol 2006; 35: 1518.
  • 45
    Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer 2006; 119: 16839.
  • 46
    Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, Sellers TA, Folsom AR. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 2002; 156: 52735.
  • 47
    Chang ET, Hjalgrim H, Smedby KE, Akerman M, Tani E, Johnsen HE, Glimelius B, Adami HO, Melbye M. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 2005; 97: 2108.
  • 48
    Hartley BE, Searle AE, Breach NM, Rhys-Evans PH, Henk JM. Aggressive cutaneous squamous cell carcinoma of the head and neck in patients with chronic lymphocytic leukaemia. J Laryngol Otol 1996; 110: 6945.
  • 49
    Hsu CW, Krevsky B, Sigman LM, Thomas RM. Rapid progression of Barrett's esophagus to metastatic esophageal carcinoma in a patient with chronic lymphocytic leukemia. J Clin Gastroenterol 1998; 27: 2614.
  • 50
    Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 245460.
  • 51
    Hjalgrim H, Frisch M, Pukkala E, Tulinius H, Ekbom A, Dictor M, Langmark F, Hardarson S, Melbye M. Risk of second cancers in classical Kaposi's sarcoma. Int J Cancer 1997; 73: 8403.
  • 52
    World Health Organization Classification of Tumours. Lyon: IARC Press, 2001.